Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Shexiang Baoxin Pill on Coronary Microvascular Dysfunction

NCT04984954 is registered in ClinicalTrials.gov with Shanghai Hutchison Pharmaceuticals Limited as lead sponsor.

NCT NCT04984954
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04984954 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Shexiang Baoxin Pill on Coronary Microvascular Dysfunction
Lead sponsor
Shanghai Hutchison Pharmaceuticals Limited
Phase
Phase 4
Overall status
Unknown status
Start date
January 28, 2021
Completion date
June 30, 2024
Enrollment
264 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

angina pectoris, coronary heart disease, non obstructive coronary artery disease, x syndrome, angina